Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Roche targets asthma with inhalable JAK1 blocker

The team headed by Nico Ghilardi targeted of Janus Kinase 1 (JAK1) with an inhalable small molecule inhibitor for two reasons:...

British F2G Biotech bags €24m

F2G Biotech said it will be spending most of the assets to push forward pivotal clinical trials of its lead compound Olorofim (F901318), a Phase IIb...

Afyren raises €21m to launch production plant

Together with its historical shareholders AFY Partners and Sofimac Régions Afyren has raised more than €60m to move its zero-waste fermentation...

uniqure delivers POC for hemophilia B gene therapy

AMT-061, an AAV5 vector, expresses a gene cassette with the Padua variant of Factor IX, which lacks in hemophilia B patients. According to uniqure,...

EMA greenlights two orphan drugs and two biosimilars

Two of six new meds to be approved in Europe are biosimilar medicines and have been backed by the European Medicines Agency (EMA) this...

Sandoz’ antiinfectives partner Ares Genetics gets fund

The subsidiary of Curetis announced to use a new €1.3m fund provided by Vienna Business Agency to develop a prototype solution for the...

New cheap CRS-blockers at the horizon

In mice, the team headed by Bert Vogelstein and Shibin Zhou from Johns-Hopkins University in Baltimore demonstrated that severe...